Patents by Inventor Christoph Gaul

Christoph Gaul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
    Patent number: 9789118
    Abstract: The present invention provides compounds of formula (IV); or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (IV), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: October 17, 2017
    Assignee: NOVARTIS AG
    Inventors: David Weninger Barnes, Gregory Raymond Bebernitz, Kevin Clairmont, Scott Louis Cohen, Robert Edson Damon, II, Robert Francis Day, Stephanie Kay Dodd, Christoph Gaul, Hatice Belgin Gulgeze Efthymiou, Monish Jain, Rajeshri Ganesh Karki, Louise Clare Kirman, Kai Lin, Justin Yik Ching Mao, Tajesh Jayprakash Patel, Brian Kenneth Raymer, Su Liansheng
  • 17a-hydroxylase/C17,20-lyase inhibitors
    Patent number: 9339501
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: May 17, 2016
    Assignee: NOVARTIS AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
  • 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS
    Publication number: 20150209356
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Application
    Filed: April 9, 2015
    Publication date: July 30, 2015
    Applicant: Novartis AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
  • 17?-hydroxylase/C-lyase inhibitors
    Patent number: 9029399
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: May 12, 2015
    Assignee: Novartis AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
  • Migrastatin analogs in the treatment of cancer
    Patent number: 8957056
    Abstract: In one aspect, the present invention provides a method for treating colon and/or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, -R, Q, Y1, Y2 and n are as defined herein, wherein the compound is present in an amount effective to inhibit colon and/or ovarian tumor metastasis.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: February 17, 2015
    Assignee: Sloan-Kettering Instiute for Cancer Research
    Inventors: Samuel J. Danishefsky, Christoph Gaul, Jón T. Njardarson, Malcolm A. S. Moore, Kaida Wu, David C. Dorn, Mihirbaran Mandal
  • 17?-hydroxylase/C-lyase inhibitors
    Patent number: 8946260
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: February 3, 2015
    Assignee: Novartis AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Henrik Moebitz, Saumitra Sengupta
  • Migrastatin analogs and uses thereof
    Patent number: 8835693
    Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis, wherein R1-R6, Ra-Rc, Q, Y1, Y2 and n are as defined herein.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: September 16, 2014
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Christoph Gaul, Jon T. Njardarson
  • 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS
    Publication number: 20140228386
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Application
    Filed: April 27, 2012
    Publication date: August 14, 2014
    Applicant: NOVARTIS AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
  • INHIBITORS OF CYP 17
    Publication number: 20140228394
    Abstract: The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Application
    Filed: April 21, 2014
    Publication date: August 14, 2014
    Applicant: Novartis AG
    Inventors: Mark Gary BOCK, Christoph GAUL, Venkateshwar Rao GUMMADI, Saumitra SENGUPTA
  • BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF
    Publication number: 20140171363
    Abstract: The present invention provides compounds of formula (I); or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (I), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Gregory Raymond BEBERNITZ, Kevin CLAIRMONT, Scott Louis COHEN, Robert Edson DAMON, II, Robert Francis DAY, Stephanie Kay DODD, Christoph GAUL, Hatice Belgin GULGEZE EFTHYMIOU, Monish JAIN, Rajeshri Ganesh KARKI, Louise Clare KIRMAN, Kai LIN, Justin Yik Ching MAO, Tajesh Jayprakash PATEL, Brian Kenneth RAYMER, SU Liansheng
  • Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
    Patent number: 8697739
    Abstract: The present invention provides compounds of formula (I); or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (I), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: April 15, 2014
    Assignee: Novartis AG
    Inventors: David Weninger Barnes, Gregory Raymond Bebernitz, Kevin Clairmont, Scott Louis Cohen, Robert Edson Damon, Robert Francis Day, Stephanie Kay Dodd, Christoph Gaul, Hatice Belgin Gulgeze Efthymiou, Monish Jain, Rajeshri Ganesh Karki, Louise Clare Kirman, Kai Lin, Justin Yik Ching Mao, Tajesh Jayprakash Patel, Brian Kenneth Raymer, Liansheng Su
  • 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS
    Publication number: 20140045872
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.
    Type: Application
    Filed: September 14, 2011
    Publication date: February 13, 2014
    Applicant: NOVARTIS AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Henrik Moebitz, Saumitra Sengupta
  • MIGRASTATIN ANALOGS AND USES THEREOF
    Publication number: 20140011844
    Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis, wherein R1-R6, Ra-Rc, Q, Y1, Y2 and n are as defined herein.
    Type: Application
    Filed: November 30, 2012
    Publication date: January 9, 2014
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Samuel J. Danishefsky, Christoph Gaul, Jon T. Njardarson
  • Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors
    Patent number: 8420657
    Abstract: The invention relates to compounds of formula I and salts thereof wherein the substituens are as defined in the specification, processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: April 16, 2013
    Assignee: Novartis AG
    Inventors: Christoph Gaul, Marc Gerspacher, Philipp Holzer, Carole Pissot Soldermann
  • Migrastatin analogs and uses thereof
    Patent number: 8324284
    Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis, wherein R1-R6, Ra-Rc, Q, Y1, Y2 and n are as defined herein.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: December 4, 2012
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Christoph Gaul, Jon T. Njardarson
  • Inhibitors of CYP 17
    Patent number: 8263635
    Abstract: The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: September 11, 2012
    Assignee: Novartis AG
    Inventors: Mark G. Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
  • Migrastatin analog compositions and uses thereof
    Patent number: 8202911
    Abstract: In one aspect, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of general formula (I), wherein R1-R6, Ra-Rc, Q, Y1, Y2 and n are as defined herein, whereby the composition is formulated for administration to a subject at a dosage between about 0.1 mg/kg to about 50 mg/kg of body weight. In another aspect, the present invention provides a method for treating breast tumor metastasis in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the inventive composition described directly above and a pharmaceutically acceptable carrier, adjuvant or vehicle.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: June 19, 2012
    Assignees: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Xin-Yun Huang, Samuel J. Danishefsky, Christoph Gaul, Jón T. Njardarson
  • ORGANIC COMPOUNDS
    Publication number: 20120142685
    Abstract: The present invention provides a compound formula I: (formula I) said compound is inhibitor of selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example MARK1/2/3, PKD-1/2/3, PKN-1/2, CDK-9, CaMKII, ROCK-I/II, inhibitors of histone deacetylase (HDAC) phosphorylation, or inhibitors of other kinases. Finally, the present invention also provides a pharmaceutical composition.
    Type: Application
    Filed: April 4, 2008
    Publication date: June 7, 2012
    Inventors: Markus Rolf Dobler, Charles Francis Jewell, JR., Erik Meredith, Lauren G. Monovich, Sarah Siska, Anette Von Matt, Maurice Van Eis, Taeyoung Yoon, Christoph Gaul, Michael Paul Capparelli
  • Quinoxaline derivatives as tyrosine kinase activity inhibitors
    Patent number: 8193189
    Abstract: The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7; R2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8; R3, R4, R5 and R6 are each independently hydrogen or R9; and R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: June 5, 2012
    Assignee: Novartis AG
    Inventors: Marc Gerspacher, Pascal Furet, Eric Vangrevelinghe, Carole Pissot Sondermann, Christoph Gaul, Philipp Holzer
  • Inhibitors of CYP 17
    Patent number: RE45173
    Abstract: The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: September 30, 2014
    Assignee: Novartis AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gunmadi, Saumitra Sengupta